

# Lee Harland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7401254/publications.pdf>

Version: 2024-02-01

24  
papers

1,405  
citations

566801

15  
h-index

713013

21  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2834  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug discovery FAQs: workflows for answering multidomain drug discovery questions. Drug Discovery Today, 2015, 20, 399-405.	3.2	24
2	Precompetitive activity to address the biological data needs of drug discovery. Nature Reviews Drug Discovery, 2014, 13, 83-84.	21.5	14
3	API-centric Linked Data integration: The Open PHACTS Discovery Platform case study. Web Semantics, 2014, 29, 12-18.	2.2	44
4	Applying linked data approaches to pharmacology: Architectural decisions and implementation. Semantic Web, 2014, 5, 101-113.	1.1	41
5	Scientific Lenses to Support Multiple Views over Linked Chemistry Data. Lecture Notes in Computer Science, 2014, , 98-113.	1.0	16
6	Scientific competency questions as the basis for semantically enriched open pharmacological space development. Drug Discovery Today, 2013, 18, 843-852.	3.2	44
7	Incorporating Commercial and Private Data into an Open Linked Data Platform for Drug Discovery. Lecture Notes in Computer Science, 2013, , 65-80.	1.0	5
8	Toward interoperable bioscience data. Nature Genetics, 2012, 44, 121-126.	9.4	362
9	Building disease and target knowledge with Semantic MediaWiki. , 2012, , 391-420.		0
10	Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group. Nature Reviews Drug Discovery, 2012, 11, 730-730.	21.5	0
11	Open PHACTS: semantic interoperability for drug discovery. Drug Discovery Today, 2012, 17, 1188-1198.	3.2	274
12	Visualizing the drug target landscape. Drug Discovery Today, 2012, 17, S3-S15.	3.2	9
13	Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research. Drug Discovery Today, 2012, 17, 469-474.	3.2	58
14	Open source software in life science research. , 2012, , .		2
15	Minimum information about a bioactive entity (MIABE). Nature Reviews Drug Discovery, 2011, 10, 661-669.	21.5	80
16	BioSharing Overview. Nature Precedings, 2011, , .	0.1	0
17	Empowering industrial research with shared biomedical vocabularies. Drug Discovery Today, 2011, 16, 940-947.	3.2	20
18	Visualizing the drug target landscape. Drug Discovery Today, 2010, 15, 3-15.	3.2	50

#	ARTICLE	IF	CITATIONS
19	Drug target central. Expert Opinion on Drug Discovery, 2009, 4, 857-872.	2.5	16
20	Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nature Reviews Drug Discovery, 2009, 8, 701-708.	21.5	79
21	High-throughput electronic biology: mining information for drug discovery. Nature Reviews Drug Discovery, 2007, 6, 220-230.	21.5	82
22	Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics, 2003, 82, 269-279.	1.3	135
23	Transcriptional Regulation of the Human TATA Binding Protein Gene. Genomics, 2002, 79, 479-482.	1.3	27
24	Api-Centric Linked Data Integration: The Open Phacts Discovery Platform Case Study. SSRN Electronic Journal, 0, , .	0.4	3